RNXT RenovoRx Corporation: ערך חשבונאי למניה

RenovoRx, Inc. (RNXT) is scaling its business through a patent model for targeted drug delivery with low-cost consumables. On GURU.Markets, the book value per share trend visualizes the real cost of capital, where the indicator is fixed at 0.20. The stability of research is guaranteed by the transparent US legal framework, while diversification into pancreatic cancer treatment minimizes risks within the oncology sector.

The development of the RenovoCath system through partnerships with oncology centers requires significant capital expenditures, which directly impacts the net equity dynamics of RenovoRx, Inc. (RNXT). By analyzing the bps metric, an investor assesses the real value of a single asset minus all liabilities, determining the internal resilience of the business and the efficiency of value accumulation during the development of targeted therapy methods.